KYMR
Kymera Therapeutics Inc

837
Mkt Cap
$5.38B
Volume
215,673.00
52W High
$103.00
52W Low
$19.45
PE Ratio
-18.95
KYMR Fundamentals
Price
$68.92
Prev Close
$68.14
Open
$67.86
50D MA
$73.33
Beta
1.68
Avg. Volume
1.39M
EPS (Annual)
-$2.98
P/B
5.17
Rev/Employee
$250,382.98
Loading...
Loading...
News
all
press releases
Kymera Therapeutics Stock: A Deep Dive Into Analyst Perspectives (25 Ratings)
read more...
Benzinga·6d ago
News Placeholder
More News
News Placeholder
BTIG Research Reaffirms Buy Rating for Kymera Therapeutics (NASDAQ:KYMR)
BTIG Research reaffirmed a "buy" rating and set a $138.00 price target on shares of Kymera Therapeutics in a research note on Thursday...
MarketBeat·6d ago
News Placeholder
Kymera Therapeutics (KYMR) Upgraded to Buy: Here's Why
Kymera Therapeutics (KYMR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks·9d ago
News Placeholder
KYMR Skyrockets 82.4% in a Year: More Upside Potential in 2026?
KYMR rallied 82% in a year as KT-621 delivered strong phase Ib BroADen data and earned FDA Fast Track for atopic dermatitis.
Zacks·16d ago
News Placeholder
Kymera Therapeutics (NASDAQ:KYMR) Trading Down 4.3% - What's Next?
Kymera Therapeutics (NASDAQ:KYMR) Shares Down 4.3% - What's Next...
MarketBeat·19d ago
News Placeholder
Insider Selling: Kymera Therapeutics (NASDAQ:KYMR) CEO Sells 30,000 Shares of Stock
Kymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) CEO Nello Mainolfi sold 30,000 shares of Kymera Therapeutics stock in a transaction that occurred on Wednesday, December 31st. The stock was...
MarketBeat·20d ago
News Placeholder
Kymera Therapeutics (NASDAQ:KYMR) CEO Nello Mainolfi Sells 30,000 Shares
Kymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) CEO Nello Mainolfi sold 30,000 shares of the firm's stock in a transaction dated Wednesday, December 31st. The shares were sold at an average...
MarketBeat·21d ago
News Placeholder
Squarepoint Ops LLC Cuts Position in Kymera Therapeutics, Inc. $KYMR
Squarepoint Ops LLC reduced its position in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 32.3% during the 2nd quarter, according to its most recent filing with the Securities and Exchange...
MarketBeat·1mo ago
News Placeholder
Kymera Therapeutics (NASDAQ:KYMR) Director Bruce Booth Sells 678 Shares
Kymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) Director Bruce Booth sold 678 shares of Kymera Therapeutics stock in a transaction on Friday, December 12th. The shares were sold at an...
MarketBeat·1mo ago
News Placeholder
Insider Selling: Kymera Therapeutics (NASDAQ:KYMR) Director Sells 6,101 Shares of Stock
Kymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) Director Bruce Booth sold 6,101 shares of Kymera Therapeutics stock in a transaction dated Thursday, December 11th. The stock was sold at an...
MarketBeat·1mo ago
<
1
2
...
>

Latest KYMR News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.